Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives $7.33 Average Price Target from Analysts

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $7.3333.

A number of equities research analysts recently weighed in on the company. Citizens Jmp began coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price objective on the stock. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Finally, Citigroup began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They set an “outperform” rating on the stock.

Whitehawk Therapeutics Price Performance

Shares of NASDAQ:WHWK opened at $4.70 on Monday. Whitehawk Therapeutics has a one year low of $1.57 and a one year high of $5.49. The company has a market cap of $232.42 million, a price-to-earnings ratio of -2.80 and a beta of 0.70. The firm has a 50 day simple moving average of $3.88 and a 200 day simple moving average of $3.04.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. As a group, analysts expect that Whitehawk Therapeutics will post -1.44 EPS for the current year.

Insider Transactions at Whitehawk Therapeutics

In related news, CEO David James Lennon sold 102,395 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $3.51, for a total value of $359,406.45. Following the completion of the sale, the chief executive officer directly owned 691,154 shares in the company, valued at $2,425,950.54. This represents a 12.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the transaction, the insider directly owned 397,106 shares of the company’s stock, valued at approximately $1,445,465.84. This represents a 18.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 705,358 shares of company stock worth $2,584,564. Company insiders own 49.90% of the company’s stock.

Institutional Investors Weigh In On Whitehawk Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at about $5,414,000. Suvretta Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at about $7,030,000. Ally Bridge Group NY LLC acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at about $1,554,000. Peapod Lane Capital LLC acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at about $577,000. Finally, ABG Innovation Capital Partners III GP Ltd acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at about $51,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.